These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2044259)

  • 21. [Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation].
    Scheen AJ
    Rev Med Liege; 1998 May; 53(5):270-5. PubMed ID: 9689881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and regression of atherosclerosis with drug therapy.
    Superko HR
    Clin Cardiol; 1991 Feb; 14(2 Suppl 1):I40-7. PubMed ID: 2044258
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of hypercholesterolaemia in postmenopausal women.
    Davidson MH; Maki KC; Karp SK; Ingram KA
    Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prevention of coronary heart disease by therapy of hyperlipidemia. Between cholesterol hysteria and therapeutic realism].
    Deller M; Huth K
    Fortschr Med; 1992 Sep; 110(25):463-6. PubMed ID: 1398397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy and clinical trials.
    Jialal I; Stein D
    Curr Opin Lipidol; 1995 Dec; 6(6):U171-5. PubMed ID: 8750260
    [No Abstract]   [Full Text] [Related]  

  • 28. The use of fibrates and of statins in preventing atherosclerosis in diabetes.
    Steiner G
    Curr Opin Lipidol; 2001 Dec; 12(6):611-7. PubMed ID: 11801860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A new approach to the treatment of dyslipidemia].
    Kevelaitiene S; Slapikas R
    Medicina (Kaunas); 2008; 44(5):407-13. PubMed ID: 18541958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lipid-lowering therapy in the prevention of coronary heart disease].
    Keller U
    Schweiz Rundsch Med Prax; 1990 Sep; 79(39):1120-4. PubMed ID: 2218247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada.
    Frohlich J; Fodor G; McPherson R; Genest J; Langner N
    Can J Cardiol; 1998 Apr; 14 Suppl A():17A-21A. PubMed ID: 9594929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of clinical outcome studies among cholesterol-lowering agents.
    Lousberg TR; Denham AM; Rasmussen JR
    Ann Pharmacother; 2001 Dec; 35(12):1599-607. PubMed ID: 11793629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Looking into the crystal ball-upcoming drugs for dyslipidemia.
    George M; Selvarajan S; Muthukumar R; Elangovan S
    J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):11-20. PubMed ID: 25079474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia.
    Molcányiová A; Stancáková A; Javorský M; Tkác I
    Pharmacol Res; 2006 Sep; 54(3):203-7. PubMed ID: 16737822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    Schiel R; Bambauer R; Müller UA
    Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future in lipid diseases.
    Lancet; 1977 Oct; 2(8042):808. PubMed ID: 71610
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Which hypocholesteremic agents for which hypercholesterolemias?].
    Dairou F
    Ann Cardiol Angeiol (Paris); 1990 Dec; 39(10):591-5. PubMed ID: 2291611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.